The in vitro effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on steroid metabolism in human luteinized granulosa cells (hLGC) have been summarized as a decreased estradiol (E 2 ) production without altering either E 2 metabolism or cytochrome P450 aromatase activity. In the present study, hLGC were used to analyze the fate of different substrates for cytochrome P450 17␣-hydroxylase/17,20-lyase (P450 c17 ) in the presence or absence of TCDD. Human LGCs were plated directly on plastic culture dishes in medium supplemented with 2 IU/ml of hCG. TCDD (10 nM) or its solvent was added directly to the cells at the time of medium change, every 48 h for 8 days. The objective of the experiment was to test the hypothesis that exogenous steroid, substrate for P450 c17 , would reduce the TCDD effects on E 2 synthesis. With dehydroepiandrosterone (DHEA) (a P450 c17 product), a dose-related increase in E 2 production was observed and the effect of TCDD on lowering E 2 production disappeared. In contrast, with increasing doses, up to 10 M, of pregnenolone (P 5 ), no change in E 2 production was observed. However, 17␣-hydroxypregnenolone (17P 5 ) at 10 M produced a modest but significant increase in the E 2 production. Treatments with P 5 and 17P 5 did not alter the effect of TCDD on E 2 production. Radiolabeled substrate utilization by hLGC suggests that the principal metabolic pathway for ⌬5 substrates is the conversion to a ⌬4 product probably by a very active 3␤-hydroxysteroid dehydrogenase. We conclude that estrogen production by hLGC is limited at the level of lyase activity. Thus, these data suggest that the most likely target for the TCDDinduced inhibition of estrogen synthesis by hLGC is the 17,20-lyase activity of the P450 c17 enzyme complex. granulosa cells, steroid hormones, toxicology
INTRODUCTION
Environmental pollutants include commercially manufactured chemicals or contaminants that are generated in several industrial processes. Chlorinated dibenzo-p-dioxins belong to a family of environmental pollutants known as halogenated aromatic hydrocarbons. The most potent component of this family is 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). The lipophilic chemistry nature of TCDD, its low degree of metabolism, and its low rate of degradation in 1 Supported by NIEHS ESO06198.
the environment make TCDD a very stable and persistent compound in both the animal body and the biosphere. Several animal models have been used to study the effects of TCDD and related compounds [1, 2] . In reproduction, toxic effects of TCDD in laboratory rodents and other species have been characterized as a change in steroid hormone levels [3] . In rats, TCDD blocks ovulation with a concomitant reduction in steroid production [4, 5] , however, TCDD can inhibit ovulation without altering steroid production [6] . TCDD also decreases estrogen production from porcine granulosa cells and progesterone from porcine luteal cells in vitro [7] . It has been reported that TCDD may inhibit steroidogenesis by affecting specific steps such as mobilization of cholesterol to the inner mitochondria membrane [8] and the activity of steroidogenic P450 enzymes in the adrenals and testes [9, 10] . The acute adverse effects of TCDD in a female nonhuman primate animal model include a depression of serum estrogen levels and early fetal loss [11] [12] [13] [14] . Long-term adverse effects from a single exposure to TCDD in nonhuman primates include decreased ovarian steroidogenesis and arrest of follicle development [15] . The human corpus luteum produces large amounts of both progesterone (P 4 ) and estradiol (E 2 ). The use of human luteinized granulosa cells (hLGC) has been proven to be a good experimental model for the primate corpus luteum [16] in terms of steroid hormone production. In vitro studies of hLGC [17] and nonhuman primate luteal cells [18] suggest that the reduction in steroid production by TCDD may involve alterations in receptor-activated signal transduction pathways. We previously reported that reduction by TCDD of E 2 production by cultured hLGC is not due to an effect of TCDD on the cytochrome P450 aromatase (P450 arom ) enzyme nor on the E 2 metabolism [19] . Therefore, based on the cumulate evidence, it was hypothesized that TCDD targets the step in the steroidogenic enzyme pathway that provides androgen substrate for aromatization.
In this article, we use an approach that involves metabolism of steroid substrate for specific steroidogenic enzymes. The challenge of separating, identifying, and quantifying individual steroids was met using high-pressure liquid chromatography (HPLC) as previously reported [20] [21] [22] . Specifically, a chromatographic system using reverse phase HPLC was employed to separate steroid metabolites produced by hLGC in vitro after incubation for defined periods of time in the presence of specific radiolabeled substrates.
The primary working hypothesis is that TCDD targets the rate-limiting step of E 2 synthesis by hLGC. Steroids such as pregnenolone (P 5 ), 17␣-hydroxy pregnenolone (17P 5 ), and dehydroepiandrosterone (DHEA) can be used as a substrate for identifying cytochrome P450 17␣-hy-245 17,20-LYASE PRODUCT MODIFIES TCDD EFFECT ON hLGC droxylase/17,20-lyase (P450 c17 ) as a possible rate-limiting step. Similarly, the use of androgens such as DHEA that eventually can be substrate for P450 arom as well as androstenedione (A 4 ) [19] may well answer whether the aromatase enzyme is working under saturating conditions or is able to handle more substrate for estrogen conversion. Using these same steroid substrates in the presence or absence of TCDD, it would be possible to find which substrate is able to revert the TCDD effect on E 2 production, providing in this way evidence for identifying the target for TCDD toxicity in this model. We already demonstrate that P450 arom is neither rate limiting nor a target for TCDD in the production of E 2 [19] . The next likely possibilities are 17␣-hydroxylation or 17,20-lyase (both activities of P450 c17 ) or some earlier enzymatic step involved in the production of E 2 .
The goal of this experiment was to characterize the effect of TCDD on P450 c17 , the enzyme that produces androgen substrates for aromatization in hLGC. We tested the hypothesis that the addition of P450 c17 products, but not the addition of P450 c17 substrates, would reverse the adverse effect of TCDD on the in vitro production of estrogen by hLGC.
MATERIALS AND METHODS

Chemicals
Dulbecco Modified Eagle Medium (DMEM), antibiotic-antimycotic (10 000 units/ml penicillin G sodium, 10 000 g/ml streptomycin sulfate, and 25 g/ml amphotericin B as a Fungizone), fetal bovine and calf sera were purchased from Gibco BRL (Grand Island, NY). Pregnyl, a commercial hCG, was purchased from Organon Inc. (West Orange, NJ). TCDD was a kind gift from Dr. Steven Safe (Texas A&M University). Dimethyl sulfoxide (DMSO) was used as the TCDD solvent and was purchased from Sigma Chemical Co. (St. Louis, MO). P 5 , 17P 5 
Human LGC Culture
Granulosa cells were processed according to a protocol previously described [16] with modifications. Briefly, hLGC were obtained from a total of 27 patients undergoing assisted reproduction treatments at the Northern California Fertility Medical Center (Roseville, CA). Cells were retrieved by ultrasound-guided follicle aspiration. After oocytes and cumulus masses were removed, red blood cells (RBC) and hLGC were separated by centrifugation. The collected hLGC from each patient separately were resuspended gently with 4.0 ml DMEM. Residual RBC were removed by 40% Percoll gradient centrifugation. Human LGC were then washed twice, resuspended, and plated at 5 ϫ 10 5 cells in 3 ml/60-mm plate (17 667 cells/ cm 2 ) or at 50 000 in 0.5 ml/four-well plate (26 315 cells/cm 2 ) in DMEM supplemented with antibiotic, antimycotic, 0.02 IU/ml of hCG, and 5% fetal calf serum at 37ЊC in an atmosphere of 5% CO 2 in air. Medium was changed after 24 h of preincubation to DMEM (supplemented with antibiotic-antimycotic, 10% calf serum, and 2 IU/ml hCG) and culture continued for 48 h before the addition of treatment experiments. Plates were assigned randomly to every experimental group, being careful to match control and treated plates within each individual patient.
TCDD Treatment
TCDD was dissolved in DMSO and added directly to the plate in a ratio of 1 l/ml of conditioned medium. A final concentration of 10 nM was chosen as a treatment based on our previous studies [17, 19] . Control cells received an equal volume of TCDD solvent (DMSO). TCDD-containing medium was changed every other day for 8 days (throughout culture Day 10). An aliquot of the conditioned medium from the last day of culture was stored frozen at Ϫ20ЊC until hormone analysis. In those experiments involving steroid substrate addition, both the TCDD and the steroids were added on the same day (starting on culture Day 2).
Substrate Addition
Starting on culture Day 2, hLGC from several patients were incubated in the presence of exogenous steroid substrate at various concentrations in the presence or absence of TCDD. P 5 and 17P 5 were prepared in 100% ethanol, and 1-5 l were added to each milliliter of conditioned medium to obtain final concentrations of 0.1, 1, 5, and 10 M. DHEA, prepared in the same way, was added at a final concentration of 0.001, 0.01, 0.1, and 1 M. The steroid substrates were added every other day together with the fresh medium and were present until the end of the experiment on culture Day 10.
3␤HSD Inhibition
The Trilostane is capable of inhibiting 3␤HSD with an inhibitory constant (K i ) that ranged from 0.04 to 0.061 M for human placenta [23] , was 0.16 M for pig testes [24] , and was 0.23 M for rat adrenal microsome [25] . For monkey granulosa cells in vitro, a dose of 250 ng/ml (0.75 M) produced a 90% inhibition on P 4 production [26] ; therefore, a dose of 1 M was chosen to block 3␤HSD in this experiment. Human LGC were plated at 50 000 cells per well on a four-well plate and treated with TCDD as explained above. On Day 10 of culture, the cells were treated with P 5 or 17P 5 (3 M) in the presence or absence of Trilostane (1 M) for an additional 24 h. At the end of the incubation time, the conditioned medium was prepared for HPLC analysis of the metabolites. Cells from three different patients were included in this experiment.
Substrate for HPLC Analysis
At the end of TCDD treatment on culture Day 10, both control and TCDD-treated hLGC were incubated in serum-free medium containing a mixture of radiolabeled and cold steroid. Approximately 100 000 cpm of each substrate was added in conjunction with the unlabeled substrate (3 M for P 5 and 17P 5 , 150 nM for A 4 ). Incubations were made for limited periods of time, from 0.5 to 24 h, to determine the time when the substrate was metabolized and the radiolabeled products were best recognized. Two additional vials containing the medium plus the steroids were incubated at the same time as the cells to be used as controls for total count and recovery efficiency (usually 70%-80%). Culture medium was saved at Ϫ20ЊC until HPLC analysis.
Sample Preparation for HPLC
One-milliliter aliquots of tissue culture medium were extracted once with 5 ml diethyl ether. The organic phases were dried under a N 2 stream while in a 37ЊC water bath. One milliliter of 100% pure EtOH was then added to each dried sample and 0.5-ml aliquots of each sample were transferred into two vials (A and B), which were subsequently dried in a vacuum with a Speed Vac 
Equipment
All chromatography was performed with an Agilent model 1100 HPLC system (Agilent Technologies, Wilmington, DE) that included a model 1100 binary pump module, a thermal column compartment, and a variable wavelength detector. Radioactive peaks were detected and counted with a ␤-Ram (Inus Systems, Inc., Tampa, FL) in-line detector. All peak data (UV and radioactivity) were collected and analyzed by microcomputer using Scintflow software (Scintco, Augusta, NJ). The data are the area under the curve for each detectable peak, and they are expressed as a percentage of the total for each HPLC analysis.
HPLC of Samples
Sample steroid analytes were analyzed by reverse-phase HPLC using an Adsorbosphere C18 (5-m, 150 ϫ 4.6-mm) column (Alltech Associ-FIG. 1. TCDD effect on steroid production. Culture media was assayed on Day 10 for E 2 (A, n ϭ 13) and P 4 (B, n ϭ 6); hLGC were exposed to TCDD (10 nM) for 8 days starting on culture Day 2 and continued throughout the experiment. TCDD treatment induced a significant decrease in E 2 concentration (P Ͻ 0.05) compared with the DMSO control. There were no significant differences for P 4 concentrations. There were no differences between DMEM and DMSO control groups.
FIG. 2.
Effect of steroid substrate addition on E 2 and P 4 production. Different doses of P 5 (A, E 2 n ϭ 13; B, P 4 n ϭ 6), 17P 5 (C, E 2 n ϭ 13; D, P 4 n ϭ 6) were given to hLGC at the same time that 10 nM TCDD (open bars) for 8 days as explained earlier.
The addition of P 5 did not produce changes in the E 2 or P 4 levels at any dose. The highest dose of 17P 5 (10 M) was able to stimulate E 2 production; however, it did not change the response to TCDD. No effects of 17P 5 were observed on P 4 production. C, Control; T, TCDD treated.
ates, Inc., Deerfield, IL) and were eluted isocratically with 40%:60% (v:v) ACN:H 2 O at a 1.5 ml/min flow rate and at 37ЊC.
All detectable metabolites from samples were identified by comparison with corresponding known standards in both the radioactive and UV detection profiles.
Hormone Determination
Concentrations of P 4 , E 2 , A 4 , and DHEA in the conditioned medium were determined on Day 10 using commercial RIA kits (Diagnostic Products Corporation, Los Angeles, CA). Interassay coefficients of variation for P 4 were below 3% and for E 2 were lower than 5%.
Data Analysis
Hormonal concentrations were represented as the mean Ϯ SEM. Normality was determined by Kolmogorov-Smirnov test. For data that were not normally distributed, the values were log transformed. Comparisons between control and TCDD-treated groups were made by one-way AN-OVA followed by a pairwise multiple comparison procedure using the Student-Newman-Keuls method. For the substrate addition and TCDD treatment of block design experiment, the data were analyzed by ANOVA with repeated measures and a significance level of alpha ϭ 0.05.
RESULTS
TCDD Effects on Steroid Production
Estradiol concentrations were significantly decreased (P ϭ 0.01, n ϭ 13) by treatment from 1.6 Ϯ 0.6 to 0.8 Ϯ 0.4 ng/ml (Fig. 1A) . On the other hand, the mean P 4 concentration in conditioned medium of hLGC (Fig. 1B) decreased slightly, from 4.8 Ϯ 1.2 to 2.6 Ϯ 0.8 g/ml (P ϭ 0.06, n ϭ 6). There was no significant change between the conditioned medium (DMEM) alone and the medium plus DMSO vehicle controls; therefore, all subsequent comparisons were made using the DMSO vehicle control group. It is important to note that several attempts were made to measure A 4 and DHEA in the conditioned media but levels for these androgens were below the limit of detection of the assay used, currently 8 pg/ml.
Effect of Substrate Addition
The addition of exogenous P 5 , substrate for 17␣-hydroxylase, did not affect the production of E 2 or P 4 (Fig. 2, A  and B) , whereas the addition of 17P 5 , substrate for 17,20-lyase, significantly increased E 2 production, almost twofold (from 1.6 Ϯ 0.6 to 3.0 Ϯ 0.9 ng/ml) at the highest dose (10 M) (Fig. 2C) . P 4 concentration presented a trend to decrease (Fig. 2D) . As previously demonstrated, the addition of DHEA to the hLGC stimulated the production of E 2 , and the inhibitory effect of TCDD on E 2 production disappeared following this treatment [19] . In the present study, we observed that DHEA exponentially stimulated E 2 production in a concentration-dependent manner, to a maximum of 180 Ϯ 30 ng/ml (Fig. 3) , more than 100 times the levels of control without additional substrate (1.6 Ϯ 0.6 ng/ml). Thus, addition of just 0.01 M of DHEA increased E 2 production to a level similar to that observed with addition of three orders of magnitude higher concentrations of 17P 5 (10 M) (Fig. 3) . The inhibitory effect of TCDD on E 2 production was not observed in the presence of added DHEA (data not shown), as previously reported [19] , but was maintained when either P 5 or 17P 5 were added (Fig. 2) .
Steroid Metabolism
Human LGC from 11 different patients were used for this experiment and several time points were analyzed for each patient. Human LGC metabolized P 5 to E 2 in approximately 1 h (see Fig. 4 ), with several additional products detected. The results indicated that P 5 was principally converted to 17P 4 (Fig. 4A) , with only a fraction (from 2% to 4%) of radiolabel identified as E 2 following 1-24 h of incubation (Fig. 4B) . In only one experiment was it possible to detect androgens in the form of testosterone (T) after 6 h of P 5 substrate incubation. Human LGC metabolized 17P 5 preferentially to 17P 4 (Fig. 5) . The intermediary and product of P450 c17 , DHEA, was observed in only one experiment following 30 min and 1 h of 17P 5 substrate incubation. It is interesting to note that the level of DHEA in TCDD-treated cells was reduced by 50% while no differences between control and TCDD-treated cells were observed for 17P 4 . The final product, E 2 , appears in relatively small amounts (less than 5%) only after 4 h of incubation with 17P 5 . At 1 h of 17P 5 incubation, more than 90% of substrate was metabolized, with the majority of the products (more than 50%) being 17P 4 (Fig. 5B) ; no differences in the metabolism of 17P 5 were observed for control and TCDD-treated cells. The metabolism of A 4 showed that almost all added substrate (80%) was converted to E 2 (47%) and E 1 (7.6%), with only traces of T (1%) detected in 30 min. No differences in the level of detected metabolites were observed with or without TCDD from 0.5 to 8 h of A 4 incubation (Fig. 6 ). These data support the concept that ⌬4 substrates tend to accumulate at 17P 4 , with only small amounts being converted to androgens and estrogens, and that the potential for aromatization is high. Further, the accumulation of 17P 4 is also consistent with 3␤HSD activity being more efficient than that of P450 c17 .
3␤HSD Inhibition
On Day 10 of culture, the cells were treated with P 5 or 17P 5 (3 M) in the presence or absence of Trilostane (1 M) for an additional 24 h. At the end of the incubation time, the conditioned medium was prepared for HPLC analysis following the same protocol explained above. The metabolism of 17P 5 was primarily to 17P 4 , with 7% of the substrate remaining as 17P 5 and 59% converted to 17P 4 (Fig. 7) . Trilostane decreased the metabolism of substrate; 33% of added 17P 5 remained after incubation and 14% of substrate remained unmetabolized in cultures of cells treated with TCDD. The combination of TCDD and Trilostane further decreased 17P 5 metabolism in comparison with either treatment alone, with 60% of substrate remaining at the end of incubation. At the same time, 17P 4 product followed a similar but reversed pattern as compared with 17P 5 . Trilostane decreased the 17P 4 to 47%; TCDD did not affect the 17P 4 level, but the combination of TCDD and Trilostane decreased 17P 4 to 15%. Despite the inhibition of 3␤HSD, there were no other metabolite products of 17P 5 . On the other hand, the metabolism of P 5 was minimal, with only 2% converted to 17P 4 and more than 70% of the radiolabel recovered as P 5 substrate (Fig. 8) .
DISCUSSION
A single in vivo exposure to TCDD induces abortion and decreases the level of circulating E 2 in the laboratory macaque [14] . The fact that TCDD decreases E 2 production by hLGC has been reported [17, 19, 27] , and we previously demonstrated that this TCDD effect on E 2 production was not due to a direct effect of TCDD on P450 arom [19] . In the same study, it was demonstrated that changes in estrogen metabolism, as suggested by others [28, 29] , was not the explanation for TCDD-induced reduction in E 2 concentration. In the present article, we present the first evidence that the adverse effect of TCDD on E 2 production by hLGC is more closely related to the production of androgen, which serves as substrate for aromatization and not for the production of P 5 or 17P 5 . We were unable to detect either A 4 or DHEA with our radioimmunoassay (data not shown), and we speculate that these products are rapidly metabolized further to estrogen. This interpretation is supported by the almost complete absence of androgen metabolites in the HPLC analysis from control and treated cells, which is not surprising because of the capacity for aromatization in hLGC. Two reports have shown more than a 100-fold increase of E 2 following the addition of a high dose of DHEA [19, 27] in control hLGC and an 8-fold increase of E 2 production following 100-nM A 4 treatment on control rat granulosa cells [30] .
The primary working hypothesis was that TCDD targets the rate-limiting step of E 2 synthesis by hLGC. The experiments with substrates P 5 and 17P 5 plus the data from DHEA addition point to the 17,20-lyase as the rate-limiting step. Therefore, if P 5 were able to alleviate the adverse effect of TCDD on E 2 production, then the blockage and target for TCDD toxicity would be at a step earlier than 17␣-hydroxylation. The data presented here do not support this possibility. Alternatively, if the addition of 17P 5 were able to alleviate the adverse effect of TCDD on E 2 production, then the target for TCDD toxicity would be at least partially at the level of production of 17P 5 , i.e., the 17␣-hydroxylation activity of the P450 c17 . At the present time, it is not possible to directly measure any enzyme activity other than P450 arom , as reported earlier [19] . We found that the addition of P 5 and 17P 5 substrates did not eliminate the effect of TCDD on E 2 production at any concentration up to 10 M. In contrast, DHEA completely overcame the TCDD-induced block in hLGC, and A 4 does it on rat granulosa cells [30] ; the P 5 and 17P 5 metabolism data support the concept that the flow of these steroids in hLGC is altered by TCDD at the point of P450 c17 . Therefore, the results from P 5 metabolism studies do not support the hypothesis that TCDD is targeting at a step proximal to P450 c17 . This interpretation contrasts with that proposed for the effects of TCDD on testicular steroidogenesis in the rat, i.e., that TCDD alters early steps in steroid biosynthesis, specifically cholesterol transport to the inner mitochondria membrane [8] . It has also been suggested that the effect of the arylhydrocarbon receptor and its ligands (dioxins, such as TCDD) on the production of steroids may be a direct effect on the steroidogenic acute regulatory protein (StAR) [31] . The modest decrease we observed in P 4 production would be consistent with this possibility. However, the decrease in progestagen synthesis cannot explain the decrease in estrogen production observed here. Specifically, the production of progesterone exceeded that of estrogen by three orders of magnitude, even after TCDD treatment, suggesting that substrate supply at the level of pregnanes, even if severely inhibited, is unlikely to be limiting and that another target of toxicity must exist. Our data demonstrate that enzyme activities leading to androgen synthesis, 17␣-hydroxylase and/or 17,20-lyase, are substrate saturated, apparently rate-limiting for estrogen production, and therefore the most likely target of relevance to estrogen synthesis in hLGC. Inhibition of progesterone production by TCDD has not been a consistent finding in studies using hLGC cultures. The results of some investigations revealed a decrease in progesterone production by hLGC that were cultured in the presence of TCDD as reported here [32] . Other reports, however, have not verified these findings [19, 27] . The trend of a dose-dependent decrease in P 4 concentration in response to increasing concentrations of 17P 5 suggests that exogenous 17P 5 may compete with endogenous P 5 for 3␤ HSD conversions to their respective ⌬4 products. If true, this competition would also explain how it would be possible to observe decreased P 4 levels when 17,20-lyase inhibition resulted in a concomitant and critical increase in competition for 3␤HSD by the 17,20-lyase substrate.
In the present study, the duration of exposure of TCDD was 10 days, which is longer than many other studies investigating the effect of TCDD on steroidogenesis [27] . Early effects of TCDD may be different than those shown here and could be limited to processes upstream of P450 c17 . Because TCDD is a long-acting toxicant in vivo, we believe that the longer incubation times better simulate in vivo exposures, as evidenced by the similar effects of TCDD on estrogen production in vivo [11, 12, 14, 15] . Furthermore, it seems more likely that adverse toxic effects would be directed to a rate-limiting step rather than a process that does not regulate downstream events. In steroidogenic cells, the rate-limiting steps identified to date include StAR and P450 side chain cleavage [33, 34] . We propose therefore that the rate-limiting step in our model for the production of estrogens is P450 c17 and this step is the target of TCDD toxicity. This conclusion is supported by the findings that high concentrations of P 5 or 17P 5 did not stimulate E 2 production as did DHEA.
Questions remain regarding intracellular partitioning, i.e., events related to exogenous substrates reaching the cell, crossing the plasma membrane, and becoming available for metabolism. The results of our experiments with radiolabeled substrates and HPLC separation of the resulting products clearly indicate that the substrates were available for metabolism. From these data, we conclude that the majority of the substrates progress through the ⌬4 pathway, supporting again the idea of a rate-limiting step at the P450 c17 enzyme. In order to enhance the flux of steroid substrates toward DHEA and ultimately to E 2 , we included in the experimental protocol the use of a 3␤HSD inhibitor. This inhibitor, Trilostane, was able to maintain P 5 and 17P 5 on the pathway as ⌬5 metabolites, a pathway that is more effective for the conversion of c21 to c19 steroids in humans [35] . Similar observations were made with luteinizing granulosa cells from the rhesus macaque, in which Trilostane decreased the production of P 4 and at the same time increased E 2 , indicating an increased flux through the ⌬5 pathway when 3␤HSD was inhibited [26] . However, the data presented here do not allow analysis of the flux through the ⌬5 pathway, as no metabolism other than the production of 17P 4 was achieved by the Trilostane in the 24-h experiment. These data support the concept of a very active 3␤HSD enzyme relative to a lower and less efficient 17,20-lyase enzyme activity that is probably the rate-limiting step in the E 2 production by hLGC. In summary, the current data indicate that hLGC treated with TCDD in the presence of exogenous DHEA induced a dose-related increase in E 2 production and the effect of TCDD on lowering E 2 production disappeared. In contrast, when cells were incubated with even higher concentrations of P 5 (up to 10 M), no change in E 2 production was observed. However, when cells were incubated with 10 M 17P 5 , there was a twofold increase in the E 2 production. Treatments with P 5 and 17P 5 did not alter the effect of TCDD on E 2 production. Our data also suggest that the principal metabolic pathway for ⌬5 substrates is the conversion to a ⌬4 product, probably by a very active 3␤HSD.
The presence of P450 c17 on hLGC is controversial and not completed established by this study alone. However, our group has mounting evidence that this enzyme is present in this model system. In this article, we demonstrate that E 2 is produced without the addition of an androgen substrate, that P 5 is converted to 17P 5 , and 17P 5 is converted to DHEA. Previously, we reported high, and parallel to progesterone, production of 17P 4 by these cells [19] , and we have preliminary evidence that demonstrates the presence of P450 c17 in hLGC lysates by immunoblot as well as 17,20-lyase activity by a radiometric assay (unpublished manuscript). While cell purity was not determined directly and theca cells could be a contaminant providing additional enzyme activities, we believe that these are standard follicular aspirates that are widely accepted as containing only granulosa cells. However, even if there is theca cell contamination, the use of hLGC in culture as a model for the primate corpus luteum was validated by Stewart and VandeVoort [16] and it has been used as an experimental model for several years [17, 19] with reliable and reproducible results in term of steroid production. In addition, there can be blood contamination (depending on patient), but most of the red blood cells (RBC) are removed during the Percoll wash. Furthermore, the RBC do not plate and do not survive in culture for the 10 days. Therefore, it is considered that these cells are relatively pure granulosa cells, which spontaneously luteinize.
We conclude that one of the rate-limiting steps on hLGC estrogen production is at the level of 17,20-lyase activity (the production of DHEA) and that the inhibition of E 2 secretion by TCDD is most likely at this rate-limiting step. While these data do not allow us to clearly identify the specific target for TCDD toxicity, the accumulated evidence suggests that TCDD most likely is targeting the proposed rate-limiting step, i.e., the 17,20-lyase activity of the P450 c17 enzyme complex. At this time, we are working on specific ways to make more direct measurements of both protein amounts and enzyme activity of P450 c17 in hLGC to provide further support for this hypothesis.
